Xcout IntelSana Biotechnology, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Sana Biotechnology, Inc. among biotechnology companies — ranked by similarity to what Sana Biotechnology, Inc. actually does, not by market-cap band.
Subscribe to see Sana Biotechnology, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Sana Biotechnology, Inc. at a glance
Sana Biotechnology, Inc. is a biotechnology company headquartered in Seattle, United States. It is publicly listed (SANA) with a market capitalisation of $776.4M. Xcout tracks 20 named people at Sana Biotechnology, Inc., including Steven D. Harr (President, Chief Executive Officer & Director). Xcout recorded 13 job postings from Sana Biotechnology, Inc. in the last 90 days, naming tools such as Microsoft Dynamics 365.
Sana Biotechnology, Inc. leadership
- Steven D. HarrPresident, Chief Executive Officer & Director
- Brian D. PiperExecutive Vice President & Chief Financial Officer
- Snehal PatelSenior Vice President & Chief Technical Officer
- Aaron GrossmanExecutive VP, Chief Legal Officer & Corporate Secretary
- Dhavalkumar D. PatelExecutive Vice President & Chief Scientific Officer
- Gary MeiningerChief Medical Officer
14 more named people on record for Sana Biotechnology, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Sana Biotechnology, Inc.
Xcout recorded 13 job postings from Sana Biotechnology, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Sana Biotechnology, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Sana Biotechnology, Inc.'s hiring signals →
Top 12 Sana Biotechnology, Inc. competitors
Ranked by semantic similarity — how close each company is to Sana Biotechnology, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The firm focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
Similar biotechnology company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Similar biotechnology company
Myosana Therapeutics, Inc. is a biotechnology research company based in Seattle, Washington, pioneering non-viral gene therapy treatments for muscle diseases.
Similar biotechnology company
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Biotech
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
Similar biotechnology company
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
Similar biotechnology company
Outpace Bio, Inc. is a biotechnology company headquartered in Seattle, Washington, specializing in AI-powered protein design to advance cell therapies.
Similar biotechnology company
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Biotech
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies. These therapies are designed for the treatment of cancer and autoimmune diseases, with a facility located in Sacramento.
Similar biotechnology company
Shape Therapeutics, Inc. is a biotechnology research company founded in 2018 and headquartered in Seattle, Washington. The firm focuses on advancing the future of medicine through programmable RNA technologies and therapeutics.
Biotech
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Life Sciences
Deverra Therapeutics, Inc. is a private biotechnology company founded in 2015 and headquartered in Seattle, Washington, focused on developing drug pipelines and therapeutic solutions.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Sana Biotechnology, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Sana Biotechnology, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →